Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Heart & Vascular Centre, Brigham and Women's Hospital and Harvard Medical School, 15 Francis St, Boston, MA, 02115, USA.
CV Imaging Program, Cardiovascular Division and Department of Radiology, Brigham and Women's Hospital, Boston, USA.
Curr Cardiol Rep. 2021 Aug 19;23(10):134. doi: 10.1007/s11886-021-01564-6.
Cardiac amyloidosis is an increasingly recognized condition with a growing range of targeted therapies, but diagnosis requires a high index of suspicion and multimodality imaging expertise. Early diagnosis remains key to improving quality of life and survival. This article reviews the multimodality imaging approach to the diagnosis, differentiation, and prognosis of cardiac amyloidosis.
Recent advances in multimodality cardiac imaging have allowed for earlier diagnosis of cardiac amyloidosis resulting in earlier initiation of life-saving therapy in cases of light chain amyloidosis and life-prolonging therapy in transthyretin amyloidosis. With these advances in multimodality imaging, it is important for cardiologists and cardiac imagers to be aware of the subtleties of early disease, the appropriate diagnostic approach as well as understanding the practicalities and pitfalls that are encountered with each modality.
随着靶向治疗方法的不断增加，心脏淀粉样变性的诊断率逐渐提高，但仍需要高度怀疑和多模态影像学专业知识。早期诊断仍然是改善生活质量和延长生存时间的关键。本文综述了多模态影像学在心脏淀粉样变性的诊断、鉴别诊断和预后评估中的应用。
多模态心脏成像的最新进展使心脏淀粉样变性的早期诊断成为可能，从而使轻链淀粉样变性患者能够更早地开始挽救生命的治疗，转甲状腺素淀粉样变性患者能够进行延长生命的治疗。随着多模态影像学的这些进展，心脏病专家和心脏成像专家了解疾病的早期细微变化、适当的诊断方法以及了解每种影像学方法的实际情况和注意事项非常重要。
